EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Venus Medtech (Hangzhou)'s Enterprise Value is HK$2,527.4 Mil.
Venus Medtech (Hangzhou)'s Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-954.8 Mil. Therefore, Venus Medtech (Hangzhou)'s EV-to-FCF for today is -2.65.
The historical rank and industry rank for Venus Medtech (Hangzhou)'s EV-to-FCF or its related term are showing as below:
HKSE:02500'
s EV-to-FCF Range Over the Past 10 Years
Min: -79.26 Med: -7.76 Max: -0.72
Current: -2.65
During the past 7 years, the highest EV-to-FCF of Venus Medtech (Hangzhou) was -0.72. The lowest was -79.26. And the median was -7.76.
HKSE:02500's EV-to-FCF is ranked worse than 100% of 361
companies
in the Medical Devices & Instruments industry
Industry Median: 28.78
vs HKSE:02500: -2.65
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Venus Medtech (Hangzhou)'s EV-to-FCF
For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Medtech (Hangzhou)'s EV-to-FCF Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Venus Medtech (Hangzhou)'s EV-to-FCF falls into.
Venus Medtech (Hangzhou)'s current Enterprise Value is HK$2,527.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Venus Medtech (Hangzhou)'s Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-954.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Venus Medtech (Hangzhou)'s PE Ratio for today is calculated as:
Venus Medtech (Hangzhou)'s share price for today is HK$5.62.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Venus Medtech (Hangzhou)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.761.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Venus Medtech (Hangzhou) EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Venus Medtech (Hangzhou)'s EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Venus Medtech (Hangzhou) (HKSE:02500) Business Description
Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02500 has been successfully added to your 